145 related articles for article (PubMed ID: 8035834)
1. Cathepsin B cleavage and release of invariant chain from MHC class II molecules follow a staged pattern.
Xu M; Capraro GA; Daibata M; Reyes VE; Humphreys RE
Mol Immunol; 1994 Jul; 31(10):723-31. PubMed ID: 8035834
[TBL] [Abstract][Full Text] [Related]
2. More efficient peptide binding to MHC class II molecules during cathepsin B digestion of Ii than after Ii release.
Daibata M; Xu M; Humphreys RE; Reyes VE
Mol Immunol; 1994 Mar; 31(4):255-60. PubMed ID: 8139580
[TBL] [Abstract][Full Text] [Related]
3. Cathepsin B cleavage of Ii from class II MHC alpha- and beta-chains.
Reyes VE; Lu S; Humphreys RE
J Immunol; 1991 Jun; 146(11):3877-80. PubMed ID: 2033257
[TBL] [Abstract][Full Text] [Related]
4. Masking of a cathepsin G cleavage site in vivo contributes to the proteolytic resistance of major histocompatibility complex class II molecules.
Burster T; Macmillan H; Hou T; Schilling J; Truong P; Boehm BO; Zou F; Lau K; Strohman M; Schaffert S; Busch R; Mellins ED
Immunology; 2010 Jul; 130(3):436-46. PubMed ID: 20331476
[TBL] [Abstract][Full Text] [Related]
5. Release of DR molecules from complexes with invariant chain through the formation of a C-terminal 25 kDa invariant chain fragment.
Demotz S; Danieli C
Mol Immunol; 1993 Dec; 30(18):1623-32. PubMed ID: 8272076
[TBL] [Abstract][Full Text] [Related]
6. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides.
Mellins E; Cameron P; Amaya M; Goodman S; Pious D; Smith L; Arp B
J Exp Med; 1994 Feb; 179(2):541-9. PubMed ID: 8294865
[TBL] [Abstract][Full Text] [Related]
7. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
Carstens C; Newman DK; Bohlen H; König A; Koch N
Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
[TBL] [Abstract][Full Text] [Related]
8. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding.
Kropshofer H; Vogt AB; Hämmerling GJ
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8313-7. PubMed ID: 7667286
[TBL] [Abstract][Full Text] [Related]
9. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
[TBL] [Abstract][Full Text] [Related]
10. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.
Zhu X; Bavari S; Ulrich R; Sadegh-Nasseri S; Ferrone S; McHugh L; Mage M
Eur J Immunol; 1997 Aug; 27(8):1933-41. PubMed ID: 9295029
[TBL] [Abstract][Full Text] [Related]
11. A three-amino-acid-long HLA-DRbeta cytoplasmic tail is sufficient to overcome ER retention of invariant-chain p35.
Khalil H; Brunet A; Thibodeau J
J Cell Sci; 2005 Oct; 118(Pt 20):4679-87. PubMed ID: 16188937
[TBL] [Abstract][Full Text] [Related]
12. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
13. Amino acid substitutions in the putative MHC class II "dimer of dimers" interface inhibit CD4+ T cell activation.
Lindstedt R; Monk N; Lombardi G; Lechler R
J Immunol; 2001 Jan; 166(2):800-8. PubMed ID: 11145653
[TBL] [Abstract][Full Text] [Related]
14. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
[TBL] [Abstract][Full Text] [Related]
15. Invariant chain dissociation from class II MHC is a catalyst for foreign peptide binding.
Reyes VE; Daibata M; Espejo R; Humphreys RE
Ann N Y Acad Sci; 1994 Aug; 730():338-41. PubMed ID: 8080205
[No Abstract] [Full Text] [Related]
16. Structural analysis of invariant chain subsets as a function of their association with MHC class II chains.
Nguyen QV; Reyes VE; Humphreys RE
Arch Biochem Biophys; 1995 Feb; 317(1):128-32. PubMed ID: 7872774
[TBL] [Abstract][Full Text] [Related]
17. Effects of brefeldin A on cleavage of invariant chain to p21 and p10 and the appearance of Ii-freed class II MHC dimers.
Nguyen QV; Roskey AM; Humphreys RE
Mol Immunol; 1993 Feb; 30(2):137-44. PubMed ID: 8429832
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of peptide binding to DR molecules by a leupeptin-induced invariant chain fragment.
Demotz S; Danieli C; Wallny HJ; Majdic O
Mol Immunol; 1994 Aug; 31(12):885-93. PubMed ID: 8065372
[TBL] [Abstract][Full Text] [Related]
19. Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules.
Malcherek G; Gnau V; Jung G; Rammensee HG; Melms A
J Exp Med; 1995 Feb; 181(2):527-36. PubMed ID: 7836909
[TBL] [Abstract][Full Text] [Related]
20. Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes.
Lamb CA; Cresswell P
J Immunol; 1992 Jun; 148(11):3478-82. PubMed ID: 1588042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
